Focused on building reliable datasets, financial models, and research tools for value-minded investors. Committed to turning complex data into practical guidance for value-investing and long-term wealth.
Dr. Charlie Tian is the founder and CEO of GuruFocus.com, a leading global investment research platform established in 2004. With a Ph.D. in physics, Dr. Tian transitioned from science to finance, applying a data-driven, disciplined approach to value investing.
Sartorius AGSARTF 84 Debt-to-EBITDA is 3.83 as of Mar. 2026, which is 38% above its 10-year median of 2.78. GuruFocus rates SARTF with a GF Score™ of 84/100 and a GF Value™ of $274.03 (Modestly Undervalued). The stock has 10 warning signs investors should review. Among 467 Medical Devices & Instruments companies, Sartorius AG ranks worse than 81.16% on this metric.
Debt-to-EBITDA measures a company's ability to pay off its debt.
A high Debt-to-EBITDA ratio generally means that a company may spend more time to paying off its debt. According to Joel Tillinghast's BIG MONEY THINKS SMALL: Biases, Blind Spots, and Smarter Investing, a ratio of Debt-to-EBITDA exceeding four is usually considered scary unless tangible assets cover the debt.
The historical rank and industry rank for Sartorius AG's Debt-to-EBITDA or its related term are showing as below:
SARTF'
s Debt-to-EBITDA Range Over the Past 10 Years
Min: 1.69 Med: 2.78 Max: 6.08
Current: 4.62
During the past 13 years, the highest Debt-to-EBITDA Ratio of Sartorius AG was 6.08. The lowest was 1.69. And the median was 2.78.
SARTF's Debt-to-EBITDA is ranked worse than 81.16% of 467
companies
in the Medical Devices & Instruments industry
Industry Median: 1.57
vs SARTF: 4.62
Sartorius AG (OTCPK:SARTF) Debt-to-EBITDA Explanation
A high Debt-to-EBITDA ratio generally means that a company may spend more time to paying off its debt.
According to Joel Tillinghast's BIG MONEY THINKS SMALL: Biases, Blind Spots, and Smarter Investing, a ratio of Debt-to-EBITDA exceeding four is usually considered scary unless tangible assets cover the debt.
Sartorius AG Debt-to-EBITDA Related Terms
Sartorius AG Debt-to-EBITDA Historical Data
* Premium members only.
The historical data trend for Sartorius AG's Debt-to-EBITDA can be seen below:
* For Operating Data section: All numbers are indicated by the unit behind each term and all currency related amount are in USD. * For other sections: All numbers are in millions except for per share data, ratio, and percentage. All currency related amount are indicated in the company's associated stock exchange currency.
SARTF vs ISRG, BDX, MDLN: Debt-to-EBITDA Comparison
For the Medical Instruments & Supplies subindustry, Sartorius AG's Debt-to-EBITDA, along with its competitors' market caps and Debt-to-EBITDA data, can be viewed below:
* Competitive companies are chosen from companies within the same industry, with headquarter located in same country, with closest market capitalization; x-axis shows the market cap, and y-axis shows the term value; the bigger the dot, the larger the market cap. Note that "N/A" values will not show up in the chart.
Sartorius AG Debt-to-EBITDA vs Medical Devices & Instruments Industry
For the Medical Devices & Instruments industry and Healthcare sector, Sartorius AG's Debt-to-EBITDA distribution charts can be found below:
* The bar in red indicates where Sartorius AG's Debt-to-EBITDA falls into.
* For Operating Data section: All numbers are indicated by the unit behind each term and all currency related amount are in USD. * For other sections: All numbers are in millions except for per share data, ratio, and percentage. All currency related amount are indicated in the company's associated stock exchange currency.
In the calculation of annual Debt-to-EBITDA, the EBITDA of the last fiscal year is used. In calculating the annualized quarterly data,
the EBITDA data used here is four times the quarterly (Mar. 2026) EBITDA data.
Sartorius AG (SARTF) has a Debt-to-EBITDA of 3.83 as of Mar. 2026. Debt-to-EBITDA ratio represents the ratio of total debt to total earnings before interest, taxes, depreciation and amortization. View historical data on Sartorius AG. This is 38% above median its historical median of 2.78. Over the past decade, Sartorius AG's Debt-to-EBITDA has ranged from 1.69 to 6.08. According to the industry distribution chart, Sartorius AG ranks #379 out of 467 companies in the Medical Devices & Instruments industry, placing it in the top 81.2%.
Is Sartorius AG's Debt-to-EBITDA too high?
Sartorius AG's current Debt-to-EBITDA of 3.83 is 38% above median its 10-year median of 2.78. Over the past 10 years, this metric has ranged from a low of 1.69 to a high of 6.08. The Medical Devices & Instruments industry median Debt-to-EBITDA is 1.57. Sartorius AG's value of 3.83 is 143.9% above this industry median. Based on the distribution chart, Sartorius AG ranks #379 out of 467 companies in the Medical Devices & Instruments industry, which is in the bottom quartile relative to peers. Overall, Sartorius AG has a GF Score™ of 84/100 and is considered Modestly Undervalued, reflecting its overall financial health beyond just this single metric.
How does Sartorius AG's Debt-to-EBITDA compare to ISRG and BDX?
According to the Medical Devices & Instruments industry distribution chart, Sartorius AG ranks #379 out of 467 companies for Debt-to-EBITDA. This places Sartorius AG in the lower half of its industry. The industry median Debt-to-EBITDA is 1.57. Sartorius AG's value of 3.83 is 143.9% above this benchmark. Historically, Sartorius AG's own Debt-to-EBITDA has ranged from 1.69 to 6.08 over the past decade. While the company's 10-year median is 2.78 vs. the industry median of 1.57, Sartorius AG has consistently been above the industry average. See the competitive comparison table and distribution chart on this page for a detailed peer-by-peer breakdown.
What is a good Debt-to-EBITDA for a Medical Devices & Instruments company?
The median Debt-to-EBITDA among Medical Devices & Instruments companies is 1.57, based on 467 companies in the industry. Companies in the top quartile (top 25%) have a Debt-to-EBITDA significantly above this median, while those in the bottom quartile fall well below. However, Debt-to-EBITDA should not be evaluated in isolation — investors should consider it alongside profitability, growth, and financial strength metrics. Sartorius AG's current Debt-to-EBITDA of 3.83 is 143.9% above the industry median. Use the industry distribution chart on this page to see where any company falls relative to its peers.
What does a high Debt-to-EBITDA mean?
A high Debt-to-EBITDA can signal that a stock is expensive relative to its fundamentals. Debt-to-EBITDA ratio represents the ratio of total debt to total earnings before interest, taxes, depreciation and amortization. View historical data on Sartorius AG. For the Medical Devices & Instruments industry, the median Debt-to-EBITDA is 1.57 — values significantly above this may indicate overvaluation, while values below may suggest a bargain or underlying issues. Sartorius AG's current Debt-to-EBITDA is 3.83, which is 38% above median its own 10-year median of 2.78. However, context matters — high-growth companies often justify higher valuations. Always evaluate alongside other metrics like GF Score™ and GF Value™.
Is Sartorius AG stock overvalued right now?
Based on GuruFocus' analysis, Sartorius AG (SARTF) is currently considered Modestly Undervalued. The stock's GF Value™ is $274.03, compared to a current price of $212.80 — trading 22.3% below its estimated fair value. The current Debt-to-EBITDA is 3.83, which is 38% above median its 10-year median of 2.78 and 143.9% above the Medical Devices & Instruments industry median of 1.57. Sartorius AG's overall GF Score™ is 84/100 with 10 warning signs to review. Investors should evaluate multiple metrics — including profitability, growth, and financial strength — before making a decision.
How is Debt-to-EBITDA calculated?
Debt-to-EBITDA is calculated from a company's financial statements. For Sartorius AG (SARTF), the current Debt-to-EBITDA is 3.83 as of Mar. 2026. GuruFocus calculates this using data sourced from SEC filings and annual reports. See the calculation section and 30-year financial data on this page for the full breakdown.
Is Sartorius AG (SARTF) Overvalued in 2026?
Based on GuruFocus' analysis, Sartorius AG stock appears to be undervalued.
The current stock price of $212.80 is trading 22.3% below its estimated GF Value™ of $274.03.
GuruFocus considers Sartorius AG to be Modestly Undervalued.
Key valuation signals for SARTF:
Debt-to-EBITDA: 3.83 (38% above median its 10-year median of 2.78)
GF Value™: $274.03 vs. price of $212.80 (22.3% below fair value)
Industry Position: 143.9% above the Medical Devices & Instruments median (#379 of 467)
No single metric tells the full story. See the SARTF stock analysis page for a complete view including 30-year financials, guru trades, and insider activity.
Sartorius AG is a leading provider of bioprocessing solutions. Its bioprocess division sells equipment and consumables for upstream and downstream manufacturing of biologic drugs and focuses on single-use technology. Its laboratory products and services division offers a wide range of products for laboratory use, including scales, pipettes, and filtration equipment. As of 2024, the bioprocess and LPS divisions contributed 80% and 20% of revenue, respectively. Bioprocess is housed in its subsidiary Sartorius Stedim Biotech, of which Sartorius AG has a 72% ownership and 83% voting control. The business is geographically diverse, with revenue across Europe, Middle East, and Africa (41% of 2024 sales), the Americas (36%), and Asia-Pacific (23%). We estimate China revenue to be around 10%.
84GF Score
Get the complete analysis for SARTF
Debt-to-EBITDA is just one metric. See GF Value™, 30-year financials, guru trades, warning signs, and more.
Quick Browse
Personalize
Premium Gurus 
Create New Portfolio
SARTF has been successfully added to your 
